文献速递心律失常

猝死性心律失常综合征尸检后基因检测的应用价值

Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

研究纳入302例经专家验证的SADS病例(中位年龄24岁,65%男性),用77个原发心电疾病和心肌病基因进行二代测序,按ACMG指南分类变异。40例(13%)检出临床可操作的致病/可能致病变异,主要病因为CPVT和长QT综合征;在82个存活家庭中,联合分子尸检与临床评估将诊断率从26%提高到39%。

要点

  • SADS病例中分子尸检检出临床可操作变异比例为13%(40/302)。
  • 主要病因为CPVT(17例,6%)和长QT综合征(11例,4%)。
  • 联合分子尸检与存活亲属临床评估将诊断率从26%提高到39%。

核心结论

  • 使用ACMG指南分类变异,针对心电疾病和心肌病基因的分子尸检在SADS中检出率适中但现实可行。
  • CPVT和长QT综合征尤其是RYR2基因起主要作用,其他基因检出率极低。
  • 联合临床与遗传评估可提高诊断效用。

研究设计与样本

  • 评估302例经专家验证且DNA合适的SADS病例(中位年龄24岁,65%男性),采用包含77个原发心电疾病和心肌病基因的扩展panel进行二代测序。
  • 按ACMG共识指南分类致病和可能致病变异。
  • 在82个存活家庭中评估分子尸检联合临床评估的检出率。
  • 在SADS病例与对照之间进行基因水平罕见变异关联分析。

主要发现

  • 302例中40例(13%)检出临床可操作的致病或可能致病变异。
  • 主要病因:CPVT 17例(6%),长QT综合征11例(4%)。
  • 基因水平罕见变异关联分析显示RYR2中罕见预测有害变异富集(p = 5 × 10-5)。
  • 在存活家庭中,分子尸检联合临床评估将诊断率从26%提高到39%。

临床怎么用

  • 对SADS病例可考虑使用包含心电疾病和心肌病基因的分子尸检,并按ACMG指南分类变异。
  • 对存活亲属联合进行临床评估与遗传检测,以提高诊断率。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sudden arrhythmic death syndrome (SADS) describes a sudden death with negative autopsy and toxicological analysis. Cardiac genetic disease is a likely etiology. OBJECTIVES: This study investigated the clinical utility and combined yield of post-mortem genetic testing (molecular autopsy) in cases of SADS and comprehensive clinical evaluation of surviving relatives. METHODS: We evaluated 302 expertly validated SADS cases with suitable DNA (median age: 24 years; 65% males) who underwent next-generation sequencing using an extended panel of 77 primary electrical disorder and cardiomyopathy genes. Pathogenic and likely pathogenic variants were classified using American College of Medical Genetics (ACMG) consensus guidelines. The yield of combined molecular autopsy and clinical evaluation in 82 surviving families was evaluated. A gene-level rare variant association analysis was conducted in SADS cases versus controls. RESULTS: A clinically actionable pathogenic or likely pathogenic variant was identified in 40 of 302 cases (13%). The main etiologies established were catecholaminergic polymorphic ventricular tachycardia and long QT syndrome (17 [6%] and 11 [4%], respectively). Gene-based rare variants association analysis showed enrichment of rare predicted deleterious variants in RYR2 (p = 5 × 10-5). Combining molecular autopsy with clinical evaluation in surviving families increased diagnostic yield from 26% to 39%. CONCLUSIONS: Molecular autopsy for electrical disorder and cardiomyopathy genes, using ACMG guidelines for variant classification, identified a modest but realistic yield in SADS. Our data highlighted the predominant role of catecholaminergic polymorphic ventricular tachycardia and long QT syndrome, especially the RYR2 gene, as well as the minimal yield from other genes. Furthermore, we showed the enhanced utility of combined clinical and genetic evaluation.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lahrouchi N, Raju H, Lodder EM, et al. Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome. J Am Coll Cardiol. 2017. PMID: 28449774. doi:10.1016/j.jacc.2017.02.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。